# Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

> **NCT01569815** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 32 (actual)

## Conditions studied

- Mild and Moderate Renal Impairment

## Interventions

- **DRUG:** LCZ696

## Key facts

- **NCT ID:** NCT01569815
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569815, "Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01569815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*